Drug Overview

Vorolanib (also known as CM082, X-82, or EYP-1901) is an orally bioavailable, small-molecule multi-kinase inhibitor. It is specifically designed to target and inhibit the Vascular Endothelial Growth Factor Receptors (VEGFR) and Platelet-Derived Growth Factor Receptors (PDGFR). By blocking these pathways, vorolanib exerts potent anti-angiogenic and antineoplastic activities, essentially “starving” tumors of the blood supply they need to grow and spread.

In the clinical landscape of March 2026, vorolanib has emerged as a significant therapeutic option in both oncology and ophthalmology. A key differentiator for vorolanib compared to first-generation kinase inhibitors (like sunitinib) is its shorter half-life and reduced tissue accumulation, which were engineered to minimize systemic toxicities while maintaining therapeutic efficacy.

Generic Name: Vorolanib.
Code Names: CM082, X-82, EYP-1901.
Trade Name: Vumina (approved in China).
Drug Class: Receptor Tyrosine Kinase Inhibitor (TKI); Anti-angiogenic Agent.
Mechanism: Dual inhibition of VEGFR (all isoforms) and PDGFR (alpha and beta). Newer data also indicates activity against JAK-1, providing an additional anti-inflammatory mechanism.
Route of Administration: Oral (Tablet) or Intravitreal Insert (DURAVYU for eye diseases).
FDA Approval Status: Investigational in the U.S. As of March 2026, vorolanib is not yet FDA-approved, though it is currently in Phase 3 pivotal trials for retinal diseases. However, it was approved by the China NMPA in June 2023 for use in combination with everolimus for advanced renal cell carcinoma.

What Is It and How Does It Work? (Mechanism of Action)

Vorolanib belongs to a class of drugs that inhibit the “engines” of cell signaling called tyrosine kinases.

1. Dual Angiogenesis Inhibition

Tumors require new blood vessels to deliver nutrients and oxygen (angiogenesis).

VEGFR Blockade: Vorolanib binds to the ATP-binding sites of VEGFR-1, -2, and -3. This prevents the “vascular endothelial growth factor” from signaling the blood vessels to grow.
PDGFR Blockade: It also inhibits PDGFR, which is involved in the recruitment of pericytes (cells that stabilize new blood vessels) and the regulation of interstitial fluid pressure in tumors.

2. Differentiated Toxicity Profile

One of the most innovative aspects of vorolanib is its pharmacokinetic design.

Fast Clearance: Unlike older TKIs that stay in the system for 30–40 hours, vorolanib has a half-life of approximately 4 to 8 hours.
Intermittent Inhibition: This shorter half-life allows for “intermittent inhibition,” which has been shown in clinical trials to reduce typical TKI side effects—such as severe fatigue and cardiotoxicity—by nearly 95% compared to continuous-inhibition drugs.

3. Emerging JAK-1 Inhibition

Recent data from 2024–2026 has revealed that vorolanib also inhibits Janus Kinase 1 (JAK-1). This adds an anti-inflammatory component by reducing Interleukin-6 (IL-6) mediated inflammation, which is particularly relevant in treating conditions like Diabetic Macular Edema (DME).

Clinical Indications and Status (2026)

While not yet broadly approved globally, vorolanib is being used and studied in several key areas:

Advanced Renal Cell Carcinoma (RCC): Approved in China for patients who have failed prior TKI treatment. It is typically used in combination with everolimus or sintilimab.
Retinal Diseases (wAMD and DME): In the U.S., an intravitreal insert called DURAVYU (which slowly releases vorolanib) is in Phase 3 trials. It is intended to provide a long-acting (6-month) treatment for wet Age-Related Macular Degeneration and Diabetic Macular Edema, potentially replacing monthly injections.
Thoracic Tumors: Investigated in Phase II trials for Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) as a maintenance therapy or in combination with checkpoint inhibitors like atezolizumab.

Dosage and Administration Protocols

Dosing for vorolanib varies significantly depending on the indication and whether it is used as monotherapy or in a combination regimen.

Treatment Context	Typical Clinical Dosage
Monotherapy (Oncology)	200 mg to 300 mg once daily.
Combination (RCC)	200 mg daily plus everolimus 5 mg daily or a PD-1 inhibitor.
Maintenance (Lung Cancer)	200 mg daily on Days 1–21 of a 21-day cycle.
Administration	Taken orally, preferably at the same time each day, with food to improve absorption.
DURAVYU (Ocular)	A single intravitreal insert administered in a physician’s office, designed to last approximately 6 months.

Clinical Efficacy and Research Results

As of March 2026, clinical data has highlighted vorolanib’s effectiveness in “re-sensitizing” tumors.

Overcoming Resistance: In patients with advanced RCC who had already failed other TKIs, the combination of vorolanib and everolimus showed a significant improvement in Progression-Free Survival (PFS) compared to everolimus alone.
Ocular Durability: Phase 2 data (DAVIO trials) showed that a single vorolanib insert could maintain vision and keep the retina dry in a majority of patients for up to 6 months, significantly reducing the “treatment burden” of frequent eye injections.
Synergy with Immunotherapy: Phase 1b trials (2022–2025) combining vorolanib with pembrolizumab or nivolumab showed a manageable safety profile and encouraging objective response rates in patients with gastric and esophageal cancers.

Safety Profile and Side Effects

Due to its selective nature and fast clearance, vorolanib’s side effects are generally milder than those of sunitinib, but they still require monitoring.

Common Side Effects (>20%):

Fatigue: Feeling unusually tired or lacking energy.
Gastrointestinal: Nausea, diarrhea, and decreased appetite.
Hypertension: High blood pressure (requires regular monitoring).
Hand-Foot Syndrome: Redness, swelling, and pain on the palms and soles.
Hair Color Change: A specific “class effect” of certain TKIs where hair may lighten or turn white.

Serious Risks:

Proteinuria: Excess protein in the urine, which may indicate kidney stress.
Cardiovascular Stress: While lower than other drugs, there is still a risk of heart-related issues in patients with pre-existing risk factors.
Liver Enzyme Elevation: Periodic blood tests (ALT/AST) are necessary to ensure the liver is processing the drug safely.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, vorolanib is being utilized to study “Vascular Stability.” Because it does not potently inhibit the TIE2 receptor (unlike axitinib), it is a valuable tool for researchers investigating how to shut down leaky tumor vessels without destroying the stability of healthy vessels. In 2026, there is also intense interest in “JAK-STAT Signaling in the Retina.” Researchers are using vorolanib’s JAK-1 inhibitory properties to explore whether chronic inflammation in the eye can be reversed by sustained-release TKIs.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

Baseline BP: Establishment of a baseline blood pressure.
Urine Analysis: To check for pre-existing proteinuria.
Eye Exam: Mandatory for patients receiving the intravitreal insert.

“Do’s and Don’ts” List:

DO report any sudden, severe headaches or changes in vision immediately.
DO take the medication with food, as this helps stabilize the absorption of the drug.
DON’T miss your scheduled blood pressure checks; hypertension can often be managed with standard blood pressure medication without stopping the vorolanib.
DON’T take over-the-counter supplements like St. John’s Wort, which can interact with the liver enzymes that break down vorolanib.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Vorolanib is a prescription-strength tyrosine kinase inhibitor. In the United States, it is currently an investigational drug available only through clinical trials. Always consult with a qualified oncologist or ophthalmologist regarding your specific diagnosis and treatment options.